SCHEMBL3487776

SCHEMBL3487776

Nc1ccc2oc(C(=O)O)cc2c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 2/20 0.76
PIM1 P11309 9/20 0.66
PIM2 Q9P1W9 4/20 0.60
LMNA P02545 2/20 0.57
TP53 P04637 1/20 0.57
CA2 P00918 1/20 0.56
CSNK2A1 P68400 3/20 0.56
CSNK2A2 P19784 2/20 0.56
CSNK2B P67870 2/20 0.56
CSNK2A3 Q8NEV1 2/20 0.56
NPC1 O15118 1/20 0.50
TSHR P16473 2/20 0.49
KDM4E B2RXH2 2/20 0.49
GLA P06280 2/20 0.49
HPGD P15428 2/20 0.49
HSD17B10 Q99714 2/20 0.49
MAPT P10636 1/20 0.49
HTT P42858 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31060249 0.86 FLT3 (1.00) FLT3PIM1PIM2LMNACA2
SCHEMBL11465166 0.86 PIM1 (0.61) FLT3PIM1PIM2LMNATP53
SCHEMBL6021894 0.85 FLT3 (0.76) FLT3PIM1PIM2LMNATP53
SCHEMBL3488095 0.83 FLT3 (0.73) FLT3PIM1PIM2LMNATP53
SCHEMBL27448783 0.83 FLT3 (0.54) FLT3PIM1PIM2LMNATP53
SCHEMBL7567706 0.81 FLT3 (0.65) FLT3PIM1TP53CSNK2A1CSNK2A2
SCHEMBL14994660 0.81 FLT3 (0.75) FLT3NPC1TSHRHPGDMAPT
SCHEMBL7410565 0.81 PIM1 (0.66) FLT3PIM1PIM2LMNATP53
SCHEMBL648526 0.81 FLT3 (0.76) FLT3PIM1PIM2LMNATP53
SCHEMBL25256269 0.79 PIM1 (0.64) FLT3PIM1PIM2LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109438403-A A kind of preparation method of 5- aminobenzofur -2- Ethyl formate 凯瑞斯德生化(苏州)有限公司 2019-03-08 CN claimed
CN-112543764-B Amide compound with BET proteolytic induction effect and medical application thereof 田边三菱制药株式会社 2024-05-10 CN disclosed
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-01-03 US disclosed
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2021-09-16 US disclosed
EP-3819305-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2021-05-12 EP disclosed
CN-112543764-A Amide compound with BET proteolysis induction effect and medical application thereof 田边三菱制药株式会社 2021-03-23 CN disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 US disclosed
WO-2020009176-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF 田辺三菱製薬株式会社 2020-01-09 WO disclosed
CN-109626550-A The application of 5,6- dihydro -4- hydroxyl -6- methylthiophene [2,3-b] sulphur pyrans -7,7- dioxide 凯瑞斯德生化(苏州)有限公司 2019-04-16 CN disclosed
CN-109626550-A The application of 5,6- dihydro -4- hydroxyl -6- methylthiophene [2,3-b] sulphur pyrans -7,7- dioxide 凯瑞斯德生化(苏州)有限公司 2019-04-16 CN disclosed
EP-1064281-B1 BENZOHETEROCYCLIC DISTAMYCIN DERIVATIVES, PROCESS FOR PREPARING THEM, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA ITALIA SPA (IT) 2005-05-25 EP disclosed
EP-0937070-B1 BENZOHETEROCYCLIC DISTAMYCIN DERIVATIVES, PROCESS FOR PREPARING THEM, AND THEIR USE AS ANTITUMOR AND ANTIVIRAL AGENTS PHARMACIA ITALIA SPA (IT) 2003-12-03 EP disclosed
EP-0738722-B1 5-Amino-benzofuran-2-carboxylic acid derivatives MERCK PATENT GMBH (DE) 2003-06-25 EP disclosed
US-6458768-B1 ANTITUMOR AGENTS THAT CAN BE FORMULATED WITH A COMPOUND ALTERNATIVELY, CAN BE ADMINISTERED IN A MIXTURE OF DRUGS PHARMACIA & UPJOHN, S.P.A. (IT) 2002-10-01 US disclosed
EP-1064281-A1 BENZOHETEROCYCLIC DISTAMYCIN DERIVATIVES, PROCESS FOR PREPARING THEM, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN S.p.A. (IT) 2001-01-03 EP disclosed
US-6153642-A Benzoheterocyclic distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents PHARMACIA & UPJOHN S.P.A. (IT) 2000-11-28 US disclosed
WO-1999050266-A1 BENZOHETEROCYCLIC DISTAMYCIN DERIVATIVES, PROCESS FOR PREPARING THEM, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 1999-10-07 WO disclosed
EP-0937070-A1 BENZOHETEROCYCLIC DISTAMYCIN DERIVATIVES, PROCESS FOR PREPARING THEM, AND THEIR USE AS ANTITUMOR AND ANTIVIRAL AGENTS PHARMACIA & UPJOHN S.p.A. (IT) 1999-08-25 EP disclosed
WO-1998021202-A1 BENZOHETEROCYCLIC DISTAMYCIN DERIVATIVES, PROCESS FOR PREPARING THEM, AND THEIR USE AS ANTITUMOR AND ANTIVIRAL AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 1998-05-22 WO disclosed
EP-0738722-A1 5-Amino-benzofuran-2-carboxylic acid derivatives MERCK PATENT GmbH (DE) 1996-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof BET1, BRD4, PHKB FLT3 2895/4885PIM1 1555/4885PIM2 2022/4885
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF BET1, BRD4, PHKB FLT3 2905/4885PIM1 1558/4885PIM2 1970/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK FLT3 407/4885PIM1 489/4885PIM2 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.